PO-0203 Pcr Analysis For Neurotropic Viruses In Suspected Meningitis Is A Cost-effective Intervention: A Retrospective Observational Study

2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A312.2-A312
Author(s):  
S Rao ◽  
A Shastri
2019 ◽  
Vol 4 (2) ◽  
pp. 67-70
Author(s):  
Ilil Maidatuz Zulfa ◽  
Fitria Dewi Yunitasari ◽  
Nisa Dwi Ratnadi

ABSTRAKBronkopneumonia adalah salah satu manifestasi klinik dari pneumonia yang paling sering muncul pada anak. Obat yang diresepkan seringkali mengkombinasikan antibiotik dengan obat-obat simtomatis dan tidak sedikit yang berupa polifarmasi. Peresepan polifarmasi berpotensi pada kurang efisiennya pengobatan. Peresepan yang kurang efisien akan berakibat pada efektivitas dan keamanan terapi, eksaserbasi atau perpanjangan gejala dan penyakit, serta tingkat keamanan pada pasien, serta peningkatan biaya terapi. Tujuan dari penelitian ini adalah untuk mengevaluasi peresepan terapi bronkopneumonia pada anak. Studi observasional secara retrospektif dilakukan pada peresepan bronkopneumonia anak usia 0-14 tahun di Unit Rawat Jalan Rumah Sakit Umum Daerah Syarifah Ambami Rato Ebu Bangkalan, Indonesia selama tahun 2016. Evaluasi peresepan mengacu pada WHO prescribing indicator yang terdiri dari 5 poin. Hasil evaluasi pada penelitian ini menunjukkan bahwa rata-rata jumlah obat yang diresepkan adalah 4,60 item per kunjungan, obat generik diresepkan sebanyak 53,88%, antibiotik sebesar 69,31%, obat injeksi sebesar 0,99%, dan obat dalam Formularium Nasional tahun 2017 sebesar 48,28% dalam satu tahun periode peresepan. Sehingga, terdapat empat indikator yang belum sesuai dengan yang ditentukan WHO. Walaupun pemberian antibiotik sangat disarankan pada terapi bronkopneumonia, peresepan antibiotik masih memerlukan evaluasi lebih lanjut terkait rasionalitasnya. Selain itu, rendahnya peresepan berdasarkan Formularium Nasional tahun 2017 menunjukkan masih relatif rendahnya optimasi penggunaan obat yang cost-effective menurut kebijakan nasional.Kata kunci: Bronkopneumonia, Peresepan, Rawat Jalan.ABSTRACTBronchopneumonia is one of pneumonia manifestations commonly occur in children.The treatments usually combine antibiotics and symptomatic drugs in the form of polypharmacy.Polypharmacy can leads to inefficient treatmentsthat can cause ineffective and unsafe treatment, exacerbation or prolongation of illness, distress, harm to the patient and increasing the cost therapy.The aim of the study was to evaluate the prescribing for bronchopneumonia treatment in children. A retrospective observational study was conducted on prescriptions written for children with bronchopneumonia age 0-14 y.o in outpatient departement of Rumah Sakit Umum Daerah Syarifah Ambami Rato Ebu Bangkalan, Indonesia during 2016.WHO prescribing indicators was used to evaluate the prescribing. The result showed that the average number of medicine per encounter was 4.60 items, including medicine prescribed by generic name was 53.88%, antibiotics prescribed was 69.31%, injection prescribed was 0.99%, and medicines prescribed from National Formulary 2017 was 48.28%. Hence, there were four indicators found to be innapproppriate to WHO recomendation. Although antibiotics are highly recommended in bronchopneumonia, the usage of antibiotics still need an assessment related to its rationality. In addition, low percentage of medicines National Formulary showed low usage of cost-effective drugs based on the goverments policy.Keywords: Bronchopneumonia, Prescribing, Outpatients.


2012 ◽  
Vol 32 (S 01) ◽  
pp. S39-S42 ◽  
Author(s):  
S. Kocher ◽  
G. Asmelash ◽  
V. Makki ◽  
S. Müller ◽  
S. Krekeler ◽  
...  

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.


Sign in / Sign up

Export Citation Format

Share Document